8-K: Theriva Biologics Completes $7.5 Million Public Offering to Fund R&D and Manufacturing

Theriva Biologics successfully closed a $7.5 million public offering to support working capital, research and development, and manufacturing scale-up.

Summary

• Theriva Biologics, Inc. consummated a public offering on May 8, 2025, raising approximately $7.5 million in gross proceeds.
• The offering included 1,990,900 shares of common stock and pre-funded warrants to purchase up to 4,827,280 shares.
• Common stock purchase warrants to buy up to 6,818,180 shares were also part of the offering.
• Each share and associated common warrant was sold at $1.10, while each pre-funded warrant and associated common warrant was sold at $1.099.
• The company plans to use the proceeds for working capital, general corporate purposes, research and development, and manufacturing scale-up.
• A portion of the funds may also be used for investments in or acquisitions of other products, businesses, or technologies.
• As of May 8, 2025, after the offering, there are 4,773,358 shares of common stock outstanding, assuming no exercise of the pre-funded or common warrants.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company successfully raised capital, which is a positive development. However, the offering involves dilution and the company's future success depends on the execution of its plans.

Positives

• The successful completion of the $7.5 million public offering strengthens the company's financial position.
• The raised capital will support critical activities such as research and development and manufacturing scale-up.
• The company has flexibility to use a portion of the proceeds for strategic investments or acquisitions.

Negatives

• The offering involved the issuance of a significant number of new shares and warrants, which could dilute existing shareholders.
• The company will incur placement agent fees and other offering expenses, reducing the net proceeds available for operations.
• The company's stock price is $1.10, which is relatively low and may indicate investor concerns.

Risks

• The company's intended use of proceeds includes potential acquisitions, which carry inherent risks of integration and execution.
• The company's success depends on the progress and outcomes of its research and development programs, which are subject to uncertainty.
• The company's stock price could be negatively impacted by market conditions or company-specific events.

Future Outlook

The company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes, including for research and development and manufacturing scale-up, and may use a portion of the proceeds to invest in or acquire other products, businesses or technologies.

Industry Context

The capital raise allows Theriva Biologics to continue its operations in the competitive biotechnology industry, where funding is crucial for research, development, and clinical trials. The company's focus on cancer therapeutics aligns with the growing demand for innovative treatments in oncology.

Comparison to Industry Standards

• Comparable companies in the biotechnology sector, such as Actinium Pharmaceuticals and Diffusion Pharmaceuticals, have also recently undertaken public offerings to fund their clinical programs.
• The size of Theriva Biologics' offering ($7.5 million) is relatively small compared to larger pharmaceutical companies but is typical for clinical-stage biotechs.
• The use of proceeds for R&D and manufacturing scale-up is a common strategy in the biotech industry, as these activities are essential for advancing drug candidates through the development pipeline.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• The company's employees will benefit from the increased funding for research and development and manufacturing scale-up.
• The company's customers and patients may benefit from the development of new therapeutics for cancer and related diseases.

Next Steps

• The company will allocate the net proceeds to working capital, general corporate purposes, research and development, and manufacturing scale-up.
• The company may explore potential investments in or acquisitions of other products, businesses, or technologies.
• The company will continue to execute its clinical development programs for its lead candidates.

Key Dates

Keywords

public offering, Theriva Biologics, common stock, pre-funded warrants, common warrants, capital raise, financing, TOVX